Antimicrobial resistance (AMR) is rapidly becoming a global crisis that could claim 40 million lives by 2050. In this video, we explore why pharmaceutical companies are reluctant to develop new ...

the pharma-backed AMR Action Fund has made its first investments in companies trying to tackle the pressing problem of antibiotic resistance. The Fund – set up as a public-private partnership by ...

“In response to the growing global demand for new antibiotics, AstraZeneca is one of the few large pharmaceutical companies involved in the research and development of new therapies addressing ...